<p><b>A</b>) Effect of erlotinib on growth of directly xenografted lung tumors. Data are plotted as mean ± SEM. <b>B</b>) Real-time PCR of Mig6 on directly xenografted tumors. Data are plotted as mean ± SD after normalization with GAPDH. <b>C</b>) Immunoblot analysis of protein lysates of lung xenografts. <b>D</b>) Efficiency of erlotinib in inhibiting growth of tumor xenografts was displayed from most sensitive (left) to most resistant (right) as a bar graph. Relative expression of Mig6 in each tumor xenograft is displayed underneath the tumor growth inhibition bar as a heatmap. FC: fold change. Scale used was Log<sub>2</sub>FC.</p
<p><b>A</b>) Immunoblot analysis of phospho-AKT, total AKT, and loading control β-actin in SCC-S and...
An important mediator of tumorigenesis, the epidermal growth factor receptor (EGFR) is expressed in ...
Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and s...
<p>Head and neck (with PC-3 as prostate), bladder, and lung were treated with indicated doses of erl...
The sensitivity of only a few tumors to anti-epidermal growth factor receptor EGFR tyrosine kinase i...
Objectives The therapeutic scheme for non-small cell lung cancer (NSCLC) patients can be improved if...
<p><b>A</b>) Cells were transfected with either control siRNA, or siRNA targeting Mig6 and erlotinib...
Supplementary Figure 6. Analysis of BBT-176 using in vivo models. A, Body weight changes in Ba/F3 EG...
Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has b...
<p>A. The control xenograft was composed largely of compact tissue with only a minority of loose, le...
International audienceThe benefit of EGFR-TKI in non-small cell lung cancer has been demonstrated in...
Abstract Purpose:To delineate gene expressionpatterns andprofile changes inmetastatic tumor biopsies...
<p>(A) Summary of the tumors in gefitinib and erlotinib-treated patients, including three drug-sensi...
<p>(a) Exposure to erlotinib in MTS assay: HCC827 (EGFR exon 19 deletion) exhibited significant grow...
<p>Whole cell lysates were prepared from the indicated cell lines, and MIG-6 was determined by weste...
<p><b>A</b>) Immunoblot analysis of phospho-AKT, total AKT, and loading control β-actin in SCC-S and...
An important mediator of tumorigenesis, the epidermal growth factor receptor (EGFR) is expressed in ...
Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and s...
<p>Head and neck (with PC-3 as prostate), bladder, and lung were treated with indicated doses of erl...
The sensitivity of only a few tumors to anti-epidermal growth factor receptor EGFR tyrosine kinase i...
Objectives The therapeutic scheme for non-small cell lung cancer (NSCLC) patients can be improved if...
<p><b>A</b>) Cells were transfected with either control siRNA, or siRNA targeting Mig6 and erlotinib...
Supplementary Figure 6. Analysis of BBT-176 using in vivo models. A, Body weight changes in Ba/F3 EG...
Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has b...
<p>A. The control xenograft was composed largely of compact tissue with only a minority of loose, le...
International audienceThe benefit of EGFR-TKI in non-small cell lung cancer has been demonstrated in...
Abstract Purpose:To delineate gene expressionpatterns andprofile changes inmetastatic tumor biopsies...
<p>(A) Summary of the tumors in gefitinib and erlotinib-treated patients, including three drug-sensi...
<p>(a) Exposure to erlotinib in MTS assay: HCC827 (EGFR exon 19 deletion) exhibited significant grow...
<p>Whole cell lysates were prepared from the indicated cell lines, and MIG-6 was determined by weste...
<p><b>A</b>) Immunoblot analysis of phospho-AKT, total AKT, and loading control β-actin in SCC-S and...
An important mediator of tumorigenesis, the epidermal growth factor receptor (EGFR) is expressed in ...
Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and s...